Keytruda

Pembrolizumab, the active ingredient in Keytruda, is a monoclonal antibody presented as a powder for solution for infusion for intravenous use. It treats a range of advanced cancers, including melanoma, non‑small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and other PD‑1‑expressing solid tumors in adult patients.

GNH USA supplies Keytruda, ensuring a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on global quality assurance and regulatory compliance.

Keytruda (pembrolizumab) targets the PD‑1 pathway and is indicated for several advanced solid tumors and lymphomas.

- Melanoma: improves overall survival and progression‑free survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer: extends survival in adults with advanced NSCLC whose tumors express PD‑L1. - Head and neck squamous cell carcinoma: provides durable responses in recurrent or metastatic disease after platinum therapy. - Classical Hodgkin lymphoma: achieves high response rates in relapsed or refractory disease after prior treatments. - Urothelial carcinoma: offers clinical benefit in locally advanced or metastatic bladder cancer with high PD‑L1 expression.

Pembrolizumab may cause a range of immune‑related adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue - Nausea - Rash or pruritus - Diarrhea - Infusion‑related reactions (fever, chills)

Serious or Rare Side Effects: - Immune‑mediated pneumonitis - Colitis leading to severe diarrhea - Hepatitis with elevated liver enzymes - Endocrinopathies (thyroiditis, adrenal insufficiency) - Severe infusion reactions or anaphylaxis

When using Keytruda, clinicians should observe several safety precautions to minimize immune‑related toxicity and ensure proper handling.

- Monitor for immune‑related adverse events: assess organ function regularly and intervene early. - Evaluate baseline hepatic, renal and endocrine status before initiation. - Avoid concurrent live vaccines: immunosuppression may reduce vaccine efficacy. - Use with caution in pregnancy: safety data are limited; discuss risks with patient. - Discontinue or hold treatment for grade 3–4 toxicities: follow established management guidelines. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Pembrolizumab can interact with other therapies, primarily affecting immune modulation and infection risk.

Major Interactions (Avoid): - Concurrent use with other immune checkpoint inhibitors: may increase toxicity. - Live attenuated vaccines: heightened risk of infection. - Strong systemic immunosuppressants (e.g., high‑dose steroids) during therapy: may reduce efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding if immune‑mediated thrombocytopenia occurs. - Non‑live vaccines: schedule appropriately as immune response may be altered. - CYP450 substrates: although minimal metabolism, monitor for unexpected effects when combined with biologics.